Stability studies trends

10 Jul 2018

Dr Ramesh Jagadeesan, Sr. Director - Analytical Development at Recipharm, speaks to CPhI Online on the trends and challenges involved with conducting stability studies for firms that supply to multiple countries, and the advantages of using a contractor.

Globalisation and stricter quality rules are changing how firms test drug stability according to Dr Ramesh Jagadeesan, Sr. Director - Analytical Development at Recipharm, who says outsourcing is the most efficient way of carrying out this vital research.

Stability studies trends

After efficacy, stability is a drug’s most important characteristic. Determining how long it stays within potency specifications during transport and storage is vital to ensuring reliable supply, planning production and deciding expiry dates.

To make this determination drug companies test their products in conditions designed to match the destination market. This, however, can be a significant challenge for firms that supply multiple countries as Karan explains.

Why do stability studies need to be market-specific?

It is important that stability studies are tailored to the market for which the product is destined. For example, in the US market, only certain products must undergo a microbiological limit test. It is possible to justify skipping this test based on the amount of water present or water activity in the final drug product.

Whereas, in the case of the European market, microbiological tests are mandatory in stability conditions. Even the limits for this test are different depending on the market.

Also, because the ICH demands different stability storage conditions for different regions, tests have to be classified into different zones depending on the temperature and humidity conditions.

Furthermore, region-specific requirements and Pharmacopeia standards differ from country to country.

Also, logistics infrastructure plays an important role in transporting the samples for analysis from the storage chambers. Some countries request that the stability study is conducted at the final packaging site.

What are the most challenging markets for which to conduct stability studies?

The challenge is not the market per se, rather the difficulty is in understanding different guidelines set by different countries and how these vary.

Korea is a good example. Korean regulators do not accept the bracketing and matrixing approach, which is a method used in the US and Europe to reduce the number of tests required. Likewise, Korean regulators require that three product batches are tested to determine the expiration dates.

While there are differing requirements, are there any trends emerging in terms of what regulators ask to be covered during stability testing?

There are some emerging patterns in the number and size of batches that regulators want. Generally, they ask for a minimum of three initial batches to be placed into a long-term stability program to assure uniformity when establishing the expiration date.

Likewise there are common demands in terms of storage conditions. Depending upon the different climatic zones, most regulators ask that tests are performed on or near 30 degrees Celsius or at exaggerated conditions.

Similarly, it is common for regulators to ask for temperature cycling and freeze-thaw studies as well as an assessment of how transportation will impact product stability.

In addition, a growing number of agencies require that, in addition to being able to determine stability, testing methods allow manufacturers to estimate the quantity of degradants and the efficacy of the container closure system.

What are the emerging trends in stability studies in terms of customer demands?

Information management is a growing area where we are experiencing greater demand from customers. Many now ask to be notified via online messaging of any temperature excursions that occur during stability testing. It is also common for customers to request that a Laboratory Information Management System (LIMS) is implemented to allow for more efficient document management.

Beyond that, there is growing interest in establishing how drug ingredients and excipients interact and impact stability during early phase product development. The idea is that this information will help guide the creation of more effective, more stable formulations.

What are the advantages of outsourcing stability studies?

Given the growing complexity of the average stability study, there are numerous advantages associated with outsourcing this work to an expert partner.

Clearly there are cost advantages to working with a CDMO that has established stability chambers and is experienced at maintaining such operations.

CDMOs with experienced staff are also beneficial. Drug companies that outsource stability testing are able to work with dedicated experts who have capacity to develop tailor-made solutions to any issues that occur.

More generally, outsourcing stability analysis will provide time for in-house scientists to concentrate on research and development activities of niche products rather than on routine testing.

In addition, contract testing labs will not show any bias when it comes to approving the product. Testing will be done in a strict GMP environment.

What factors do sponsors need to consider when choosing a contractor for stability studies?

Choosing a CDMO to conduct stability studies on your behalf is a complex process. The ideal approach is to identify the necessary criteria and review each potential supplier against this.

There are basic criteria like ensuring the contract testing lab operates its facility under cGMP conditions and has instruments complying with 21 CFR guidelines. Similarly, contract testing labs should provide various ranges of temperature and humidity storage conditions. They must also continuously monitor and maintain the stability chambers to ensure they possess all the necessary security features.

However, there are other more performance-related considerations.

For example, studies should be performed with quick response times to enable the sponsor to file the drug product on time. Therefore, it is sensible to determine how responsive the contractor is to requests and whether they have a good communication strategy in place.

Likewise, transparency is vital. If an out of specification result is logged it is important that the contractor notifies the customer in a timely fashion.

Read More

Related news

Concept Life Sciences extends GLP accreditation to support regulatory studies

Concept Life Sciences extends GLP accreditation to support regulatory studies

10 Nov 2018

Accreditation ensures quality and integrity of non-clinical laboratory studies to support pharmaceutical and biotech industries.

Read more 
Sartorius receives award for outstanding performance in its production chain

Sartorius receives award for outstanding performance in its production chain

8 Nov 2018

Company's manufacturing building for laboratory instruments in Göttingen wins the Global Excellence in Operations Award.

Read more 
Record growth at The Wasdell Group

Record growth at The Wasdell Group

7 Nov 2018

Despite Brexit looming, the company's EU & UK business has increased by almost 30% in the last 12 months.

Read more 
bioLIVE to merge with BioProduction Congress for 2019 event

bioLIVE to merge with BioProduction Congress for 2019 event

7 Nov 2018

BioProduction’s content platform will be added to the bioLIVE exhibition, creating one of the world’s largest event hubs for the bio industry.

Read more 
Proprietary nasal delivery formulation of diazepam reaches NDA

Proprietary nasal delivery formulation of diazepam reaches NDA

7 Nov 2018

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

Read more 
Croda opens its Centre of Innovation for marine biotechnology

Croda opens its Centre of Innovation for marine biotechnology

5 Nov 2018

The new Centre of Innovation for Marine Biotechnology will accelerate the company’s research and product development program to identify sustainable, natural sources of functional ingredients.

Read more 
Plasticell receives EU funding to advance neurodegenerative disease research

Plasticell receives EU funding to advance neurodegenerative disease research

1 Nov 2018

Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.

Read more 
DSCSA one-month countdown!

DSCSA one-month countdown!

30 Oct 2018

With only a month to go, it really is too late to start trying to develop an in-house solution.

Read more 
Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

30 Oct 2018

Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies.

Read more 
Elpis Biomed human cell models could potentially replace animal experiments in drug discovery

Elpis Biomed human cell models could potentially replace animal experiments in drug discovery

28 Oct 2018

OPTi-OX technology allows the company to produce human cells of unprecedented quality, purity, and consistency.

Read more